BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 26077641)

  • 1. Characteristics and behaviour of screen-detected ductal carcinoma in situ of the breast: comparison with symptomatic patients.
    Koh VC; Lim JC; Thike AA; Cheok PY; Thu MM; Tan VK; Tan BK; Ong KW; Ho GH; Tan WJ; Tan Y; Salahuddin AS; Busmanis I; Chong AP; Iqbal J; Thilagaratnam S; Wong JS; Tan PH
    Breast Cancer Res Treat; 2015 Jul; 152(2):293-304. PubMed ID: 26077641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The frequency of presentation and clinico-pathological characteristics of symptomatic versus screen detected ductal carcinoma in situ of the breast.
    Barnes NL; Dimopoulos N; Williams KE; Howe M; Bundred NJ
    Eur J Surg Oncol; 2014 Mar; 40(3):249-54. PubMed ID: 24433818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Behaviour and characteristics of low-grade ductal carcinoma in situ of the breast: literature review and single-centre retrospective series.
    Koh VCY; Lim JCT; Thike AA; Cheok PY; Thu MMM; Li H; Tan VKM; Ong KW; Tan BKT; Ho GH; Thilagaratnam S; Wong JSL; Wong FY; Ellis IO; Tan PH
    Histopathology; 2019 Jun; 74(7):970-987. PubMed ID: 30734334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of clinical-pathological characteristics between symptomatic and interval breast cancer.
    Meshkat B; Prichard RS; Al-Hilli Z; Bass GA; Quinn C; O'Doherty A; Rothwell J; Geraghty J; Evoy D; McDermott EW
    Breast; 2015 Jun; 24(3):278-82. PubMed ID: 25771080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence.
    Han K; Nofech-Mozes S; Narod S; Hanna W; Vesprini D; Saskin R; Taylor C; Kong I; Paszat L; Rakovitch E
    Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):183-9. PubMed ID: 21958729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathological and biological differences between screen-detected and interval ductal carcinoma in situ of the breast.
    de Roos MA; van der Vegt B; de Vries J; Wesseling J; de Bock GH
    Ann Surg Oncol; 2007 Jul; 14(7):2097-104. PubMed ID: 17453296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screen detected ductal carcinoma in situ (DCIS): overdiagnosis or an obligate precursor of invasive disease?
    Evans AJ; Pinder SE; Ellis IO; Wilson AR
    J Med Screen; 2001; 8(3):149-51. PubMed ID: 11678555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early detection of breast cancer through population-based mammographic screening in Asian women: a comparison study between screen-detected and symptomatic breast cancers.
    Chuwa EW; Yeo AW; Koong HN; Wong CY; Yong WS; Tan PH; Ho JT; Wong JS; Ho GH
    Breast J; 2009; 15(2):133-9. PubMed ID: 19292798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular phenotypes of DCIS predict overall and invasive recurrence.
    Williams KE; Barnes NLP; Cramer A; Johnson R; Cheema K; Morris J; Howe M; Bundred NJ
    Ann Oncol; 2015 May; 26(5):1019-1025. PubMed ID: 25678586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.
    Borgquist S; Zhou W; Jirström K; Amini RM; Sollie T; Sørlie T; Blomqvist C; Butt S; Wärnberg F
    BMC Cancer; 2015 Jun; 15():468. PubMed ID: 26062614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast density, scintimammographic (99m)Tc(V)DMSA uptake, and calcitonin gene related peptide (CGRP) expression in mixed invasive ductal associated with extensive in situ ductal carcinoma (IDC + DCIS) and pure invasive ductal carcinoma (IDC): correlation with estrogen receptor (ER) status, proliferation index Ki-67, and histological grade.
    Papantoniou V; Sotiropoulou E; Valsamaki P; Tsaroucha A; Sotiropoulou M; Ptohis N; Stipsanelli A; Dimitrakakis K; Marinopoulos S; Tsiouris S; Antsaklis A
    Breast Cancer; 2011 Oct; 18(4):286-91. PubMed ID: 20143189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mammographically detected, clinically occult ductal carcinoma in situ treated with breast-conserving surgery and definitive breast irradiation.
    Solin LJ; McCormick B; Recht A; Haffty BG; Taylor ME; Kuske RR; Bornstein BA; McNeese M; Schultz DJ; Fowble BL; Barrett W; Yeh IT; Kurtz JM; Amalric R; Fourquet A
    Cancer J Sci Am; 1996; 2(3):158-65. PubMed ID: 9166516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Invasive ductal carcinoma with coexisting ductal carcinoma in situ (IDC/DCIS) versus pure invasive ductal carcinoma (IDC): a comparison of clinicopathological characteristics, molecular subtypes, and clinical outcomes.
    Goh CW; Wu J; Ding S; Lin C; Chen X; Huang O; Chen W; Li Y; Shen K; Zhu L
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1877-1886. PubMed ID: 31089799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple-negative and HER2 positive ductal carcinoma in situ of the breast: characteristics, behavior, and biomarker profile.
    Takahashi S; Thike AA; Koh VCY; Sasano H; Tan PH
    Virchows Arch; 2018 Sep; 473(3):275-283. PubMed ID: 30033510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of screening-detected ductal carcinoma in situ treated with wide excision alone.
    Fong J; Kurniawan ED; Rose AK; Mou A; Collins JP; Miller JA; Mann GB
    Ann Surg Oncol; 2011 Dec; 18(13):3778-84. PubMed ID: 21630124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is there a low-grade precursor pathway in breast cancer?
    King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M
    Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
    Ottesen GL
    APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The method of detection of ductal carcinoma in situ has no therapeutic implications: results of a population-based cohort study.
    Elshof LE; Schaapveld M; Rutgers EJ; Schmidt MK; de Munck L; van Leeuwen FE; Wesseling J
    Breast Cancer Res; 2017 Mar; 19(1):26. PubMed ID: 28274272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does breast screening offer a survival benefit? A retrospective comparative study of oncological outcomes of screen-detected and symptomatic early stage breast cancer cases.
    Újhelyi M; Pukancsik D; Kelemen P; Kovács E; Kenessey I; Udvarhelyi N; Bak M; Kovács T; Mátrai Z
    Eur J Surg Oncol; 2016 Dec; 42(12):1814-1820. PubMed ID: 27424787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in incidence and tumour grade in screen-detected ductal carcinoma in situ and invasive breast cancer.
    Luiten JD; Voogd AC; Luiten EJT; Duijm LEM
    Breast Cancer Res Treat; 2017 Nov; 166(1):307-314. PubMed ID: 28748346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.